Loading...

We've got a brand new version of Simply Wall St! Try it out

Mesoblast

ASX:MSB
Snowflake Description

High growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MSB
ASX
A$960M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The last earnings update was 81 days ago. More info.


Add to Portfolio Compare Print
MSB Share Price and Events
7 Day Returns
-1.1%
ASX:MSB
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
36.4%
ASX:MSB
50.9%
AU Biotechs
16.3%
AU Market
MSB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Mesoblast (MSB) -1.1% 1.1% 23.2% 36.4% 46.5% -57%
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • MSB underperformed the Biotechs industry which returned 50.9% over the past year.
  • MSB outperformed the Market in Australia which returned 16.3% over the past year.
Price Volatility
MSB
Industry
5yr Volatility vs Market

MSB Value

 Is Mesoblast undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Mesoblast. This is due to cash flow or dividend data being unavailable. The share price is A$1.78.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Mesoblast's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Mesoblast's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:MSB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in USD $-0.18
ASX:MSB Share Price ** ASX (2019-11-18) in AUD A$1.78
ASX:MSB Share Price converted to USD reporting currency Exchange rate (AUD/ USD) 0.681 $1.21
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Mesoblast.

ASX:MSB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:MSB Share Price ÷ EPS (both in USD)

= 1.21 ÷ -0.18

-6.67x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mesoblast is loss making, we can't compare its value to the Global Biotechs industry average.
  • Mesoblast is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Mesoblast's expected growth come at a high price?
Raw Data
ASX:MSB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.67x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
59%per year
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Mesoblast, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Mesoblast's assets?
Raw Data
ASX:MSB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in USD $0.97
ASX:MSB Share Price * ASX (2019-11-18) in AUD A$1.78
ASX:MSB Share Price converted to USD reporting currency Exchange rate (AUD/ USD) 0.681 $1.21
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:MSB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:MSB Share Price ÷ Book Value per Share (both in USD)

= 1.21 ÷ 0.97

1.25x

* Primary Listing of Mesoblast.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mesoblast is good value based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess Mesoblast's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Mesoblast has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MSB Future Performance

 How is Mesoblast expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
59%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Mesoblast expected to grow at an attractive rate?
  • Mesoblast's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
  • Mesoblast's earnings growth is expected to exceed the Australia market average.
  • Mesoblast's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:MSB Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:MSB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 59%
ASX:MSB Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 49.5%
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:MSB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:MSB Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-06-30 786 57 363 3
2023-06-30 555 27 224 3
2022-06-30 245 -56 17 5
2021-06-30 88 -77 -66 7
2020-06-30 44 -57 -72 8
2019-11-18
ASX:MSB Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-06-30 17 -58 -90
2019-03-31 16 -59 -90
2018-12-31 16 -57 -86
2018-09-30 28 -74 -48
2018-06-30 17 -75 -35
2018-03-31 16 -78 -42
2017-12-31 16 -84 -30
2017-09-30 3 -95 -64
2017-06-30 2 -95 -77
2017-03-31 29 -90 -1
2016-12-31 32 -86 -8
2016-09-30 35 -81 -11

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Mesoblast's earnings are expected to grow significantly at over 20% yearly.
  • Mesoblast's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:MSB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Mesoblast Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:MSB Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-06-30
2023-06-30
2022-06-30 -0.04 0.08 -0.15 2.00
2021-06-30 -0.09 -0.07 -0.12 3.00
2020-06-30 -0.14 -0.09 -0.22 5.00
2019-11-18
ASX:MSB Past Financials Data
Date (Data in USD Millions) EPS *
2019-06-30 -0.18
2019-03-31 -0.18
2018-12-31 -0.18
2018-09-30 -0.10
2018-06-30 -0.08
2018-03-31 -0.09
2017-12-31 -0.07
2017-09-30 -0.16
2017-06-30 -0.19
2017-03-31 0.00
2016-12-31 -0.02
2016-09-30 -0.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Mesoblast will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Mesoblast's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Mesoblast has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MSB Past Performance

  How has Mesoblast performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Mesoblast's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Mesoblast does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Mesoblast's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Mesoblast's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Mesoblast's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Mesoblast Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:MSB Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 16.72 -89.80 21.63 59.82
2019-03-31 16.46 -89.91 21.22 65.92
2018-12-31 16.28 -86.07 21.99 68.31
2018-09-30 27.80 -47.77 22.51 69.05
2018-06-30 17.34 -35.29 21.91 65.93
2018-03-31 16.21 -41.64 23.84 64.33
2017-12-31 16.04 -30.29 23.32 61.46
2017-09-30 3.19 -64.04 22.56 60.28
2017-06-30 2.41 -76.82 23.01 58.91
2017-03-31 28.73 -1.34 21.69 57.37
2016-12-31 31.97 -8.49 21.59 55.46
2016-09-30 35.43 -10.77 22.42 52.93
2016-06-30 42.55 -4.13 22.50 50.01
2016-03-31 19.85 -83.00 24.99 54.09
2015-12-31 19.94 -88.30 26.31 55.52
2015-09-30 20.31 -93.86 28.13 60.85
2015-06-30 19.76 -96.24 29.54 62.65
2015-03-31 21.25 -84.77 26.05 55.61
2014-12-31 23.50 -84.42 24.85 55.26
2014-09-30 26.12 -75.37 24.15 50.82
2014-06-30 23.39 -75.53 24.40 50.93
2014-03-31 30.10 -67.78 23.32 49.38
2013-12-31 35.50 -57.90 21.45 46.13
2013-09-30 37.41 -56.40 21.38 45.80
2013-06-30 31.78 -56.45 20.91 43.79
2013-03-31 35.78 -60.61 25.47 47.58
2012-12-31 35.35 -56.90 27.11 45.26

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Mesoblast has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Mesoblast has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Mesoblast improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Mesoblast's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Mesoblast has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MSB Health

 How is Mesoblast's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Mesoblast's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Mesoblast is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Mesoblast's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Mesoblast's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Mesoblast Company Filings, last reported 4 months ago.

ASX:MSB Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 481.05 81.29 50.43
2019-03-31 500.94 79.58 70.39
2018-12-31 524.56 63.48 77.02
2018-09-30 527.60 61.16 55.14
2018-06-30 546.01 59.40 37.76
2018-03-31 556.14 31.42 59.54
2017-12-31 575.61 0.00 47.39
2017-09-30 559.59 0.00 62.94
2017-06-30 516.77 0.00 45.76
2017-03-31 540.40 0.00 69.12
2016-12-31 510.52 0.00 33.90
2016-09-30 509.87 0.00 60.36
2016-06-30 528.16 0.00 80.94
2016-03-31 478.94 0.00 99.93
2015-12-31 492.75 0.00 120.78
2015-09-30 452.83 0.00 77.76
2015-06-30 467.99 0.00 110.70
2015-03-31 478.60 0.00 122.09
2014-12-31 478.60 0.00 122.09
2014-09-30 512.53 0.00 149.14
2014-06-30 539.18 0.00 185.22
2014-03-31 530.08 0.00 182.09
2013-12-31 570.37 0.00 226.81
2013-09-30 589.12 0.00 297.98
2013-06-30 576.98 0.00 291.84
2013-03-31 656.01 0.00 331.82
2012-12-31 470.87 0.00 185.49
  • Mesoblast's level of debt (16.9%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Mesoblast's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Mesoblast has less than a year of cash runway based on current free cash flow.
  • Mesoblast has less than a year of cash runway if free cash flow continues to reduce at historical rates of -14.5% each year.
X
Financial health checks
We assess Mesoblast's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Mesoblast has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MSB Dividends

 What is Mesoblast's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Mesoblast dividends. Estimated to be 0% next year.
If you bought A$2,000 of Mesoblast shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Mesoblast's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Mesoblast's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:MSB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:MSB Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-06-30
2023-06-30
2022-06-30
2021-06-30 0.00 1.00
2020-06-30 0.00 1.00
2019-11-18

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Mesoblast has not reported any payouts.
  • Unable to verify if Mesoblast's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Mesoblast's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Mesoblast has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Mesoblast's dividends in 3 years as they are not expected to pay a notable one for Australia.
X
Income/ dividend checks
We assess Mesoblast's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Mesoblast afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Mesoblast has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MSB Management

 What is the CEO of Mesoblast's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Silviu Itescu
COMPENSATION $1,927,278
AGE 62
TENURE AS CEO 8.8 years
CEO Bio

Prof. Silviu Itescu, MBBS (Hons), FRACP, FACP, FACRA, FTSE has been the Chief Executive Officer and Managing Director of Mesoblast Limited since 2011. Prof. Itescu is the Chief Executive Officer at Mesoblast, Inc. He serves as a Director of Transplantation Immunology at Columbia University's New York. Prof. Itescu founded Mesoblast Limited in 2004 and served as its Chief Scientific Advisor since June 2004. He serves as Professor of Medicine at the University of Melbourne and has an outstanding international reputation in research and development in biotechnology. Prof. Itescu is on the Medical Faculties of both Columbia University in NewYork and Melbourne University. He is a faculty member of Monash University. He has established an outstanding international reputation in the fields of Cell Biology, immunology, autoimmune diseases, organ transplantation and heart failure. In these areas of focus, Prof. Itescu has gained broad experience, from basic research in the laboratory through to new drug development and clinical evaluation. He serves as the Chairman and Member of Scientific Advisory Board at Mesoblast Limited. Prof. Itescu has been an Executive Director of Mesoblast Limited since 2007 and served as its director since June 2004 until 2007. He serves as an Executive Director of Mesoblast, Inc. Prof. Itescu is a member of numerous national and international scientific bodies and professional societies, has consulted globally for many international pharmaceutical companies and has been an advisor to biotechnology and health care investment groups. Prof. Itescu served as a Member of Executive Committee of Alliance for Regenerative Medicine. He served as a Director of Diversa Limited (formelry Ambri Ltd.) from September 18, 2003 to December 20, 2006 and Zenyth Therapeutics Ltd. (formerly Amrad Corp. Ltd.) from July 17, 2003 to November 2006. He has served on the board of directors of several publicly listed life sciences companies. Prof. Itescu established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. In 2011, Prof. Itescu was named BioSpectrum Asia Person of the Year. In 2013, he received the inaugural Key Innovator Award from the Vatican’s Pontifical Council for Culture for his leadership in translational science and clinical medicine in relation to adult stem cell therapy. Prof. Itescu holds a Medical Degree from Monash University and received his Specialty Training in Internal Medicine and Immunology/Rheumatology from New York University.

CEO Compensation
  • Silviu's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Silviu's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure

Average tenure and age of the Mesoblast management team in years:

8.8
Average Tenure
60
Average Age
  • The average tenure for the Mesoblast management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Silviu Itescu

TITLE
Founder
COMPENSATION
$2M
AGE
62
TENURE
8.8 yrs

Josh Muntner

TITLE
Chief Financial Officer
COMPENSATION
$892K
AGE
50
TENURE
1.5 yrs

Peter Howard

TITLE
General Counsel & Corporate Executive
AGE
51
TENURE
8.3 yrs

Donna Skerrett

TITLE
AGE
62
TENURE
8.8 yrs

Paul Simmons

TITLE
Head of Research & New Product Development
AGE
60
TENURE
8.8 yrs

Michael Schuster

TITLE
Head of Pharma Partnering
AGE
42

John McMannis

TITLE
Head of Manufacturing
AGE
63
TENURE
8.8 yrs

Jon Symonds

TITLE
Head of Corporate Finance & Strategy
AGE
60

Julie Meldrum

TITLE
Global Head of Corporate Communications

Roger Brown

TITLE
Head of Spinal Orthopedic Disorders
TENURE
4.1 yrs
Board of Directors Tenure

Average tenure and age of the Mesoblast board of directors in years:

9.5
Average Tenure
66
Average Age
  • The tenure for the Mesoblast board of directors is about average.
Board of Directors

Joe Swedish

TITLE
Independent Non-Executive Chairman
COMPENSATION
$324K
AGE
67
TENURE
0.6 yrs

Silviu Itescu

TITLE
Founder
COMPENSATION
$2M
AGE
62

Bill Burns

TITLE
Independent Non-Executive Vice Chairman
COMPENSATION
$201K
AGE
72
TENURE
3.8 yrs

Donal O’Dwyer

TITLE
Independent Non-Executive Director
COMPENSATION
$181K
AGE
66
TENURE
15.2 yrs

Michael Spooner

TITLE
Independent Non-Executive Director
COMPENSATION
$181K
AGE
62
TENURE
15.2 yrs

Bob Graham

TITLE
Member of Scientific Advisory Board

Henry Krum

TITLE
Member of Scientific Advisory Board

Joseph Lane

TITLE
Member of Scientific Advisory Board

Richard Gilbert

TITLE
Member of Scientific Advisory Board

Stephen Graves

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
22. Oct 19 Sell Capital Research and Management Company Company 15. Mar 19 21. Oct 19 -2,076,860 A$1.87 A$-3,883,728
07. Oct 19 Buy M&G Investment Management Limited Company 04. Oct 19 04. Oct 19 5,000,000 A$2.00 A$9,999,996
11. Jul 19 Buy M&G Investment Management Limited Company 20. May 19 10. Jul 19 3,681,270 A$1.53 A$5,630,551
17. Mar 19 Sell Capital Research and Management Company Company 08. Feb 19 14. Mar 19 -8,714,117 A$1.19 A$-10,343,661
10. Feb 19 Sell Capital Research and Management Company Company 08. Mar 18 07. Feb 19 -2,721,380 A$1.22 A$-3,306,476
X
Management checks
We assess Mesoblast's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Mesoblast has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MSB News

Simply Wall St News

Mesoblast (ASX:MSB) Is Carrying A Fair Bit Of Debt

We can see that Mesoblast Limited (ASX:MSB) does use debt in its business. … Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. … The first thing to do when considering how much debt a business uses is to look at its cash and debt together.

Simply Wall St -

When Will Mesoblast Limited (ASX:MSB) Breakeven?

Check out our latest analysis for Mesoblast According to the 7 industry analysts covering MSB, the consensus is breakeven is near. … Next Steps: This article is not intended to be a comprehensive analysis on MSB, so if you are interested in understanding the company at a deeper level, take a look at MSB’s company page on Simply Wall St. … Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.

Simply Wall St -

Does Market Volatility Impact Mesoblast Limited's (ASX:MSB) Share Price?

Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … Before we go on, it's worth noting that Warren Buffett pointed out in his 2014 letter to shareholders that 'volatility is far from synonymous with risk.' Having said that, beta can still be rather useful. … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

Does Market Volatility Impact Mesoblast Limited's (ASX:MSB) Share Price?

If you're interested in Mesoblast Limited (ASX:MSB), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … This is above 1, so historically its share price has been influenced by the broader volatility of the stock market. … What this means for you: Beta only tells us that the Mesoblast share price is sensitive to broader market movements.

Simply Wall St -

Is Mesoblast Limited (ASX:MSB) Overpaying Its CEO?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … At the time of writing our data says that Mesoblast Limited has a market cap of AU$718m, and is paying total annual CEO compensation of US$2.0m. … Thus we can conclude that Silviu Itescu receives more in total compensation than the median of a group of companies in the same market, and of similar size to Mesoblast Limited.

Simply Wall St -

What Kind Of Shareholder Owns Most Mesoblast Limited (ASX:MSB) Stock?

Taking a look at our data on the ownership groups (below), it's seems that institutions own shares in the company. … Private Company Ownership We can see that Private Companies own 4.7%, of the shares on issue. … Public Company Ownership We can see that public companies hold 4.7%, of the MSB shares on issue.

Simply Wall St -

The Mesoblast (ASX:MSB) Share Price Is Down 69% So Some Shareholders Are Wishing They Sold

Because Mesoblast is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … Shareholders of unprofitable companies usually expect strong revenue growth. … That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

Simply Wall St -

When Will Mesoblast Limited (ASX:MSB) Breakeven?

With the latest financial year loss of -US$35.3m and a trailing-twelve month of -US$86.1m, the AU$711m market-cap amplifies its loss by moving further away from its breakeven target. … As path to profitability is the topic on MSB’s investors mind, I’ve decided to gauge market sentiment. … In this article, I will touch on the expectations for MSB’s growth and when analysts expect the company to become profitable

Simply Wall St -

Before You Buy Mesoblast Limited (ASX:MSB), Consider Its Volatility

If you're interested in Mesoblast Limited (ASX:MSB), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

Does Mesoblast Limited's (ASX:MSB) CEO Pay Compare Well With Peers?

In 2011 Silviu Itescu was appointed CEO of Mesoblast Limited (ASX:MSB). … This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Silviu Itescu's Compensation Compare With Similar Sized Companies?

Simply Wall St -

MSB Company Info

Description

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company’s products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.

Details
Name: Mesoblast Limited
MSB
Exchange: ASX
Founded: 2004
A$959,722,981
533,179,434
Website: http://www.mesoblast.com
Address: Mesoblast Limited
55 Collins Street,
Level 38,
Melbourne,
Victoria, 3000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX MSB Ordinary Shares Australian Securities Exchange AU AUD 16. Dec 2004
OTCPK MEOB.F Ordinary Shares Pink Sheets LLC US USD 16. Dec 2004
DB LWB Ordinary Shares Deutsche Boerse AG DE EUR 16. Dec 2004
CHIA MSB Ordinary Shares Chi-X Australia AU AUD 16. Dec 2004
NasdaqGS MESO SPON ADR EACH REP 5 SHS Nasdaq Global Select US USD 15. Dec 2005
DB LWBA SPON ADR EACH REP 5 SHS Deutsche Boerse AG DE EUR 15. Dec 2005
Number of employees
Current staff
Staff numbers
83
Mesoblast employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:31
End of day share price update: 2019/11/18 00:00
Last estimates confirmation: 2019/10/31
Last earnings filing: 2019/08/29
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.